These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
517 related articles for article (PubMed ID: 33408716)
1. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy. Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M Front Immunol; 2020; 11():601497. PubMed ID: 33408716 [TBL] [Abstract][Full Text] [Related]
2. Combining Nanomedicine and Immunotherapy. Shi Y; Lammers T Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725 [TBL] [Abstract][Full Text] [Related]
9. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy. Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626 [TBL] [Abstract][Full Text] [Related]
10. Localized Interleukin-12 for Cancer Immunotherapy. Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA Front Immunol; 2020; 11():575597. PubMed ID: 33178203 [TBL] [Abstract][Full Text] [Related]
11. Enhancing cancer immunotherapy with nanomedicine. Irvine DJ; Dane EL Nat Rev Immunol; 2020 May; 20(5):321-334. PubMed ID: 32005979 [TBL] [Abstract][Full Text] [Related]
12. Targeting tumor associated macrophages: The new challenge for nanomedicine. Andón FT; Digifico E; Maeda A; Erreni M; Mantovani A; Alonso MJ; Allavena P Semin Immunol; 2017 Dec; 34():103-113. PubMed ID: 28941641 [TBL] [Abstract][Full Text] [Related]
13. Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy. Abdelgalil RM; Elmorshedy YM; Elkhodairy KA; Teleb M; Bekhit AA; Khattab SN; Elzoghby AO Nanomedicine (Lond); 2022 Sep; 17(22):1721-1745. PubMed ID: 36621872 [TBL] [Abstract][Full Text] [Related]
14. Tumor Microenvironment-Enabled Nanotherapy. Wang L; Huo M; Chen Y; Shi J Adv Healthc Mater; 2018 Apr; 7(8):e1701156. PubMed ID: 29283221 [TBL] [Abstract][Full Text] [Related]
15. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology. Li W; Wei H; Li H; Gao J; Feng SS; Guo Y Nanomedicine (Lond); 2014 Nov; 9(16):2587-605. PubMed ID: 25490427 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy. Duan X; Chan C; Lin W Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571 [TBL] [Abstract][Full Text] [Related]
18. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Huang KW; Hsu FF; Qiu JT; Chern GJ; Lee YA; Chang CC; Huang YT; Sung YC; Chiang CC; Huang RL; Lin CC; Dinh TK; Huang HC; Shih YC; Alson D; Lin CY; Lin YC; Chang PC; Lin SY; Chen Y Sci Adv; 2020 Jan; 6(3):eaax5032. PubMed ID: 31998834 [TBL] [Abstract][Full Text] [Related]
19. Cancer Nanomedicine: Lessons for Immuno-Oncology. Sengupta S Trends Cancer; 2017 Aug; 3(8):551-560. PubMed ID: 28780932 [TBL] [Abstract][Full Text] [Related]
20. Advances in Multiple Stimuli-Responsive Drug-Delivery Systems for Cancer Therapy. Jia R; Teng L; Gao L; Su T; Fu L; Qiu Z; Bi Y Int J Nanomedicine; 2021; 16():1525-1551. PubMed ID: 33658782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]